West Virginia University Logo

April 16, 2014


SAMHSA Prescription Drug Abuse Weekly Update
Issue 67  |  April 16, 2014
The Prevention of Prescription Drug Abuse in the Workplace (PAW) TA Center addresses prescription drug abuse—a growing public health problem with increasing burdens on workers, workplaces, and our economy. To subscribe colleagues, family members, or friends to this listserv sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA), please click here or send their e-mail addresses to paw@dsgonline.com.
Table of Content Featured Article Journal Articles and Reports Professional News Other State and Local News Other Resources Webinar Grant Announcements Grants Awarded Take-Back Events and Drop Boxes Save the Dates Upcoming Conferences and Workshops


E.L. Mozurkewich and W.F. Rayburn. 2014. "Buprenorphine and Methadone for Opioid Addiction During Pregnancy." Obstetrics and Gynecology Clinics of North America, doi:10.1016/j.ogc.2014.02.005.

This article highlighted five points on buprenorphine and methadone use for opioid addiction during pregnancy: 1) opioid substitution therapy with methadone or buprenorphine during and after pregnancy and postpartum improves maternal and neonatal outcomes; 2) physiologic changes of pregnancy such as increases in maternal weight, intravascular volume, and renal elimination of drugs necessitate increased dosage of opioid substitution medications during the second and third trimesters; 3) methadone therapy may be associated with higher treatment satisfaction and treatment retention in comparison with buprenorphine therapy; 4) the only well-recognized adverse effect of opioid substitution therapy is neonatal abstinence syndrome, which is common but not dose dependent; and 5) compared with methadone therapy, buprenorphine therapy reduces duration and severity of neonatal abstinence syndrome.

Read more:

New Mexico Pharmacists to Prescribe Anti-Overdose Drug
The Santa Fe New Mexican
March 28, 2014

New Mexico is the first state authorizing pharmacists to prescribe naloxone, and recently trained its first 60 pharmacists on prescribing Narcan to patients. One reason the prescribing authority was granted to pharmacies is because New Mexico is so rural, which creates access problems for patients seeking physician care. Under a protocol developed by the New Mexico Board of Pharmacy, all pharmacists registered and practicing within New Mexico may prescribe naloxone.

Read more:

Journal Articles and Reports

B.E. Denham. 2014. "High School Sports Participation and Substance Use: Differences by Sport, Race, and Gender." Journal of Child & Adolescent Substance Abuse 23(3):145–54, doi:10.1080/1067828X.2012.750974.

Using data from the 2009 Monitoring the Future Survey and controlling for race, self-esteem, and noncompetitive exercise frequency, this research examined the explanatory effects of competitive sports participation on alcohol consumption, marijuana use, and nonmedical use of prescription pain relievers among high school seniors. Among males, football players used all three substances at comparably high levels. Females with low self-esteem smoked marijuana and used prescription drugs more frequently.

Read more:

S.C. Matson, G. Hobson, M. Abdel–Rasoul, and A.E. Bonny. 2014. "A Retrospective Study of Retention of Opioid-Dependent Adolescents and Young Adults in an Outpatient Buprenorphine/Naloxone Clinic." Journal of Addiction Medicine, doi:10.1097/ADM.0000000000000035.

This chart-based study described 1-year retention and compliance of outpatient medication-assisted treatment with buprenorphine/naloxone for 103 opioid-dependent white non-Hispanic adolescents and young adults treated in 2010. Only 75 percent of patients returned for a second visit. Patient retention was 45 percent at 60 days and 9 percent at 1 year. Female sex (p < 0.05), negative urine drug screen for opioids (p < 0.001) or tetrahydrocannabinol (p < 0.001), and positive urine drug screen for buprenorphine/naloxone (p < 0.001) were associated with longer retention time.

Read more:

J.B. McKinlay, F. Trachtenberg, L.D. Marceau, J.N. Katz, and M.A. Fischer. 2014. "Effects of Patient Medication Requests on Physician Prescribing Behavior: Results of a Factorial Experiment." Medical Care 52(4):294–99, doi:10.1097/MLR.0000000000000096.

Two experiments were conducted with 192 primary care physicians from six states. Each used video-based scenarios: an undiagnosed patient with symptoms strongly suggesting sciatica, and a patient with previously diagnosed chronic knee osteoarthritis. Half of patients with sciatica symptoms requested oxycodone; the other half requested something to help with pain. Similarly, half of knee osteoarthritis patients requested Celebrex; half requested something to help with pain. Among sciatica patients, 19.8 percent of those who requested oxycodone received a prescription compared with 1 percent of those who made no specific request (p=0.001). Fifty-three percent of knee osteoarthritis patients who requested Celebrex received it compared with 24 percent of patients who made no request (p=0.001). Patients requesting oxycodone were more likely to receive a strong narcotic (p=0.001) and less likely to receive a weak narcotic (p=0.01). Those requesting Celebrex were much less likely to receive a nonselective nonsteroidal anti-inflammatory drug (p=0.008). No patient attributes, physician, or organizational factors influenced a physician's willingness to accede to a patient's medication request.

Read more:

H.L. Surratt, C. O'Grady, S.P. Kurtz, Y. Stivers, T.J. Cicero, R.C. Dart, and M. Chen. 2014. "Reductions in Prescription Opioid Diversion Following Recent Legislative Interventions in Florida." Pharmacoepidemiology and Drug Safety 23(3):314–20, doi:10.1002/pds.3553.

Florida legislative interventions implemented in 2010–11 included better regulation of pain clinic operations and a statewide prescription drug monitoring program. The authors fit hierarchical linear models to law enforcement data on diversion rates over 15 quarters. Oxycodone, methadone, and morphine diversion declined significantly. A hydrocodone diversion decline was marginally significant; buprenorphine, fentanyl, and tramadol diversion were unchanged.

Read more:

R.D. Weiss, J. Sharpe Potter, M.L. Griffin, R.K. McHugh, D. Haller, P. Jacobs, J. Gardin, D. Fischer, and K.D. Rosen. 2014. "Reasons for Opioid Use Among Patients with Dependence on Prescription Opioids: The Role of Chronic Pain." Journal of Substance Abuse Treatment, doi:10.1016/j.jsat.2014.03.004.

This study examined reasons for prescription opioid use among 653 participants (with and without chronic pain) enrolled in a randomized controlled trial of treatment for prescription opioid dependence. Participants with chronic pain were more likely to report pain as their main initial reason for use; avoiding withdrawal was rated as the most important reason for current use in both groups. Participants with chronic pain rated using opioids to cope with physical pain as more important, and using opioids in response to social interactions and cravings as less important than those without chronic pain.

Read more:

Professional Education News and Editorial

B.P. Dunleavy. 2014. "Potential Hydrocodone-Combination Product Rescheduling Sparks Debate." Clinical Pain Medicine 12(4).

The Food and Drug Administration and Drug Enforcement Administration (DEA) submitted a joint proposal to reclassify hydrocodone combination products that include the opioid analgesic from Schedule III to Schedule II controlled substances. The DEA is "in the process of drafting the notice of proposed rulemaking," which will be published in the Federal Register for comment. The American Pharmacists Association, American Society of Consultant Pharmacists, National Community Pharmacists Association, and National Association of Chain Drug Stores oppose the change. The American Academy of Pain Medicine (AAPM) neither supports nor opposes the reclassification, but worries the move could limit patient access to needed treatment and result in less effective—or more dangerous—drugs being prescribed. AAPM also thinks a schedule change may increase costs for insurers and patients. The American Society of Addiction Medicine applauded the proposal.

Read more:

G.J. Muller. 2014. "Addressing After-Hours Requests for Prescription Drugs." Journal of the American Dental Association 145(4):389–90, doi:10.14219/jada.2014.13.

Dr. Muller, an oral and maxillofacial surgeon and member of the American Dental Association (ADA) Council on Ethics, Bylaws, and Judicial Affairs, responds to a reader who asks "What is the ethical way to deal with after-hours callers who may turn out to be drug seekers?" Dr. Muller suggests using ADA's Principles of Ethics and Code of Professional Conduct as a guide. The dentist should determine if a patient's concern is actually an emergency, and identify what is beneficial versus harmful for the patient. It is also advisable to probe the nature and veracity of the patient's claim by asking questions such as, "Are you seeing or have you been seen by any other provider for this problem?" and "What medications are you currently taking for this problem?" If a patient lies, the dentist should not prescribe an opioid.

Read more:

J.R. Roberts. 2014. "InFocus: Fentanyl-Laced Heroin: A Deadly Combination." Emergency Medicine News 36(4):13–15, doi:10.1097/01.EEM.0000446051.11866.98.

This article discusses heroin and fentanyl use and how to treat overdoses with naloxone. Fentanyl will respond to naloxone administration, but greater doses may be required. Although deadly heroin laced with fentanyl has been in the news, a fentanyl manufacturer in Mexico closed, markedly reducing problems in the United States. Pure fentanyl overdose resembles heroin or morphine overdose, typically needing 5–6 mg of naloxone. The author recommends keeping those who respond to naloxone in the emergency room for at least 4–5 hours because the drug wears off and residual opioid can retrigger symptoms.

Read more:


Maine Medicaid Rules Reduce Narcotic Prescriptions
The Washington Post
April 10, 2014

Implementing Medicaid restrictions on opioid pain relievers in Maine led to a 17 percent drop (15,000 patients) in those taking the drugs in 2013 compared with 2012. With fewer prescriptions and smaller doses, the number of pills dispensed was cut 27 percent (6 million pills). By comparison, numbers of patients on opioids and pills prescribed rose among Medicare, workers' compensation, and self-pay patients. The new Medicaid rules limit patients to pain relievers for 2 weeks a year, allowing renewal in 2-week intervals with special permission. Patients with chronic pain lasting beyond 8 weeks are required to try alternative treatments such as physical, cognitive–behavioral, chiropractic, or pain acceptance therapy.

Read more:

Blue Cross Cuts Back on Painkiller Prescriptions
The Boston Globe
April 8, 2014

In July 2012, Blue Cross and Blue Shield of Massachusetts began an 18-month effort that reduced prescriptions by 20 percent (6.6 million pills) for short-acting opioids such as Percocet, and 50 percent for longer-lasting drugs like OxyContin. Patients now need authorization from Blue Cross for more than 30 days of short-acting opioid pain relievers within a 2-month period. They are allowed to fill a 15-day prescription and one 15-day refill. Before more medication is prescribed, the patient is assessed for addiction risk, and a treatment plan is agreed upon by the prescriber and patient. For longer-acting pain relievers, prior authorization from the insurer is now required. Case managers are also working among Blue Cross's 2.8 million members to enhance access to pain management specialists and explore non-narcotic alternatives.

Read more:

Senate Tackles Prescription Drug Abuse
The Hill
April 10, 2014

Senate Health, Employment, Labor and Pensions Committee Chairman Tom Harkin and Ranking Member Lamar Alexander announced the bipartisan Prescription Drug Abuse Working Group and invited lawmakers to join efforts cracking down on abuse and misuse. The Working Group will examine the extent of prescription drug abuse throughout the country and explore innovative ways law enforcement and healthcare providers can address the problem.

Read more:

Zohydro Maker Sues to Block Massachusetts Ban
ABC News
April 8, 2014

In March, Massachusetts' governor Deval Patrick declared a public health emergency in response to the state's growing heroin and opioid addiction epidemic. Governor Patrick gave the state's public health commissioner certain emergency powers, including banning Zohydro "until determined that adequate measures are in place to safeguard against the potential for diversion, overdose, and misuse." Zogenix, the maker of Zohydro, filed a lawsuit in federal court to block the ban. Zogenix argues the governor's order is at odds with the Food and Drug Administration.

Read more:

A Look at Heroin Use, Deaths in Some US States
The Associated Press
April 5, 2014

This article provides statistics on use, overdoses, and treatment of heroin from 26 states with no summative overview. The data comes from Associated Press queries to state health departments, medical examiners' offices, and law enforcement agencies.

Read more:

Oxycodone: The Factors Behind Australians' Increasing Use of 'Hillbilly Heroin'
April 7, 2014

Dispensed use of oxycodone rose 180 percent in Australia from 2002 to 2009, with a much larger rise among the elderly. A prescription drug black market is also thriving online. Among 204 drug treatment patients in Victoria, Queensland, Western Australia, and Tasmania in 2013, half said they frequently used oxycodone, 86 percent said their prescription opioid use had become a problem, and 80 percent said they initially used the medication for pain relief. Australia's approaches to the issue include a real-time prescription drug monitoring program and shifting to tamper-resistant oxycodone.

Read more:

Coming Soon to a Neighborhood Near You: Adderall Abuse
The Huffington Post
April 8, 2014

This article discusses growing abuse of stimulant medications among adults, the majority of those who use legally produced stimulants in the United States. Adult misuse and abuse of amphetamines dates back to 1927. Amphetamines are the number-one drug for admissions at substance abuse rehabilitation hospitals in California. James Swanson and Nora Volkow of the National Institute on Drug Abuse suggest up to 30 percent of legally produced stimulants in the United States are being diverted for illegal use.

Read more:

Naloxone 'Stigma' a Barrier to Prescribing?
MedPage Today
April 9, 2014

This article discusses the stigma surrounding naloxone use among patients and doctors. Dr. Caleb Banta–Green at the University of Washington said patients may feel they are being treated like addicts and that their opioid prescriptions will be tempered, while doctors worry just talking about naloxone may scare patients away. Dr. Phillip Coffin of the San Francisco Public Health Department studied patient perceptions of naloxone and found worries largely stem from chronic pain patients who fear they will be denied needed medications. Dr. Leo Beletsky at Northeastern University said defeating the stigma will likely be determined by patient demand. If patients start asking for naloxone, prescriptions will increase.

Read more:

Commentary: Let's Get Serious About Treating Addiction
Partnership at Drugfree.org
April 9, 2014

David L. Rosenbloom, a professor at Boston University School of Public Health and former director of Join Together, shares seven policy changes he believes will end America's refusal to prevent and treat addiction. The policies include 1) completing the transition to individual health insurance with coverage for addiction treatment; 2) integrating addiction, mental illness, and medical treatment around individuals with severe addiction; 3) increasing insurance payment rates for addiction treatment to a level that meets providers' costs, draws in new responsible providers, and pays for required coordination; 4) rewarding longer stays in treatment and terminating use of providers who cannot successfully retain patients in treatment long enough to be effective; 5) requiring hospitals, health centers, HMOs, and other primary providers—as a condition of their participation in Medicaid, Medicare, and public employee health programs—to demonstrate they diagnose all patients with alcohol and drug disease and have a clinically sound program that gets individuals appropriate care; 6) stopping the revolving door at detoxification programs; and 7) stopping arrests for nonviolent drug offenses.

Read more:

New System Allows Safe Disposal of Unused Prescription Medications
Pharmaceutical Online
April 7, 2014

Mallinckrodt Pharmaceuticals and Verde Environmental Technologies have partnered to create Verde Medsaway, a disposal pouch for home medication that will be available at doctors' offices and clinics. The pouch promotes responsible disposal of unused prescription medications. When medicine is placed in the pouch and mixed with water, the activated carbon binds with the drug's active ingredients to make them physiologically inactive. The used pouch can be discarded in the regular trash.

Read more:

Tracing the U.S. Heroin Surge Back South of the Border as Mexican Cannabis Output Falls
The Washington Post
April 6, 2014

This article discusses Mexican cartels' change in production of cannabis to planting opium poppies. Drug Enforcement Administration officials say the spread of heroin in the United States is the result of a marketing strategy developed by Mexican traffickers. They have targeted areas with the worst prescription pill abuse, sending heroin pushers to set up right outside methadone clinics. Colombia and Mexico account for more than 90 percent of the U.S. heroin supply, and nearly all of it is smuggled into the country by Mexican traffickers.

Read more:

Overprescribed Opiates Fueling Heroin OD Epidemic in MA
April 10, 2014

A prescription drug monitoring program study found 40 percent of Massachusetts residents were prescribed an opioid during their lifetime. Leftover prescriptions are often kept in the home and can be misused. When people run out of pills, especially if they are addicted, heroin becomes a likely replacement because it offers a similar effect at a lower price. Thus, prescription opioids are a root cause of heroin addiction and overdoses.

Read more:

Other State and Local News

Painkillers Might Not Be Right Prescription for Veterans
April 10, 2014

This article, video (5:17 minutes), and audio (9:05 minutes) discuss Veterans Administration (VA) efforts to help veterans manage pain and pain reliever use in San Diego. Opioid use has more than doubled within the San Diego VA system. Roughly 13,000 of the 76,000 veterans enrolled at the San Diego VA are taking prescribed pain relievers. Nearly 5,000 veterans fill recurring prescriptions for the drugs. Since the VA began addressing the problem 1 year ago, pain reliever prescriptions have dropped slightly—from 18.2 percent to 17.2 percent.

Read more:

Doctors Could Face Drug Database Requirement for Prescriptions
CBS Miami
April 10, 2014

The Florida House Health and Human Services Committee approved requiring physicians to access the state prescription drug monitoring program (PDMP) before prescribing controlled substances to new patients. The proposal was added to an omnibus healthcare bill (HB 7113) and drew objections from the Florida Medical Association and other physician groups. HB 7113 would also earmark $500,000 during the 2014 fiscal year to administer the PDMP.

Read more:

Six Percent of CSU Students Abuse Prescription Drugs Like Adderall, Ritalin
Collegian Central
April 10, 2014

The National College Health Assessment reported that Colorado State University's (CSU's) rate for prescription drug abuse is only about 6 percent, which is comparable to the national average. The Health Network monitors prescription drug use at CSU. It started programs with CREWS, the Network's peer education team, to educate students about prescription abuse dangers.

Read more:

Report: Overdose-Death Watch Is Lacking
The Enid News and Eagle
April 7, 2014

This article discusses gaps in Oklahoma's enforcement efforts to identify, investigate, and pursue problem providers. For example, Dr. Joshua Livingston saw 60 to 100 patients a day at his South Pointe Pain Clinic in Tulsa. Four of his patients died of overdoses. After the first death in August 2011, 18 months passed before Livingston's prescribing practices were restricted. The medical examiner's office typically takes at least 2 to 3 months to complete a death investigation report and send it to the state's narcotics bureau. The prescription drug monitoring program is also underused by enforcement authorities.

Read more:

Minnesota Senate Passes Overdose Protection Bill
April 8, 2014

This article and video (1:58 minutes) discuss "Steve's Law," which the Minnesota Senate recently passed and sent to the House. This Good Samaritan law provides criminal protection to those who call 911 when someone has overdosed. The bill would also allow more people to administer emergency anti-overdose medication.

Read more:

Mothers of Opioid-Exposed Newborns Find Treatment at Vermont Clinic
NBC News
April 8, 2014

This photo gallery shows the life of two mothers who are trying to stay clean and cope with the consequences of drug addiction as well as the impact on their children.

Read more:

Possible Compromise Is Reached on 'Doctor-Shopping' Legislation
April 11, 2014

Under a potential compromise reached at the State Capitol, Oklahoma doctors would be required to check patients' drug histories once a year before writing a narcotic prescription. Senate Bill 1820 is aimed at deterring "doctor shopping" by patients who fill multiple prescriptions written by different physicians. Currently, doctors are not required to check the prescription drug monitoring program database. A spokesman for the Oklahoma State Medical Association said the group's leadership planned to review the proposed compromise over the weekend.

Read more:

Addicted Oklahoma: How Can Oklahoma Combat Doctor-Shopping?
April 7, 2014

This article includes the transcribed conversation that Jaclyn Cosgrove at The Oklahoman and Warren Vieth from the Oklahoma Watch had with readers about the state's prescription drug abuse and overdose problem. The two media entities partnered for a special report to raise awareness about this issue and persuade leaders to find a better solution.

Read more:

R.I. Has Tools to Spot Prescription Abusers, but Few Prescribers Use Them
Providence Journal
April 6, 2014

Only about 20 percent of people licensed to prescribe controlled substances have signed up to use Rhode Island's prescription drug monitoring program (PDMP) since it became available online in September 2012. The PDMP is consulted for fewer than 10 percent of all prescriptions written for controlled substances. Rhode Island law does not require patients to show a valid driver's license or government-issued identification before they are given a controlled substance. The vast majority of practitioners in the state still write prescriptions for controlled substances on paper.

Read more:

The Epidemic Began with an Effort to Reduce Pain; for Donna Read, That Effort Led to Oxycodone
Providence Journal
April 5, 2014

This article discusses Rhode Island resident Donna Read's battle with back pain, oxycodone dependence, and the process it took to wean her completely off opioids. It also discusses the state's efforts to stop opioid overprescribing and lack of a multidisciplinary pain center.

Read more:

Overdosed: Addicts Easily Game a System with Fraudulent Prescriptions/Video
Providence Journal
April 6, 2014

This article and video 4:23 (minutes) discuss how Jonathan Whitkin supported his addiction to pain relievers by forging hundreds of prescriptions. During a 4-month period in 2004, Whitkin filled more than 100 prescriptions at 34 different pharmacies in Massachusetts. He has been convicted of more than 70 felony drug charges in Rhode Island and Massachusetts and has served more than 3 years in state prisons. Law enforcement officials say prescription drug forgery is helping to fuel addiction and overdose deaths. Prosecutions of Rhode Island prescription drug fraud in 2012 and 2013 increased 40 percent from the previous 2 years. Experts say the crimes are significantly underreported.

Read more:

Legislation Would Make Prescription Drop Box Mandatory at Every Police Station
Record-Journal (Connecticut)
April 11, 2014

This article discusses House Bill 5392, which would require the Connecticut Department of Emergency Services and Public Protection to create a program for the collection and disposal of unwanted medications. The bill, which was referred to the legislature's Appropriations Committee, would require every municipal and state police department to install a secure drop box available to the public 24/7. The program would also require that pharmaceuticals be transported to a biomedical waste facility for incineration.

Read more:

Governor Signs Three Anti-Heroin Bills
April 7, 2014

Wisconsin's governor signed seven bills aimed at reducing heroin use. The bills allow all emergency responders with training to administer Narcan, provide a measure of immunity for anyone who calls 911 to report an overdose, require patients to show identification for prescription drugs containing narcotics, and allow municipalities to hold prescription drug collection drives.

Read more:

Other Resources

Drug Take-Back Toolkit
C.A.R.E.S. Alliance
Accessed April 10, 2014

The C.A.R.E.S. Alliance developed this online toolkit to provide guidance and best practices learned from previous take-back events. The kit includes event-planning instructions and template materials that can be customized to engage partners and promote events.

Read more:


Girls and Substance Use: Trends, Challenges, and Opportunities
April 22, 2014
3–4:30 p.m.

Grant Announcements

2014 Prescription Drug Abuse and Misuse Prevention Grant Program
Cardinal Health Foundation
Deadline: April 25, 2014


FY 14 Harold Rogers Prescription Drug Monitoring Program
Bureau of Justice Assistance, Department of Justice
Deadline: May 6, 2014

Prescription Drug Overdose: Boost for State Prevention
Centers for Disease Control and Prevention
Deadline: June 4, 2014

The purpose of this funding is to advance and evaluate comprehensive state-level interventions for preventing prescription drug misuse, abuse, and overdose. Interventions of interest will address patient and prescriber behaviors that drive the prescription drug overdose epidemic, particularly misuse and inappropriate prescribing of opioid pain relievers. Specifically, awardees will perform activities that support at least two of the following complementary key prevention strategies: enhancing and maximizing prescription drug monitoring programs; improving and evaluating state health insurance mechanisms to prevent prescription drug misuse, diversion, and overdose (e.g., via Medicaid or workers' compensation); and evaluating state-level laws, policies, and regulations (e.g., legislation regulating pain clinics or supporting clinical practice guidelines).

Read more:

Grants Awarded

Scientists Win Grant to Study How Exposure to Prescription Pain Medication in the Womb Affects Developing Brain
April 9, 2014

Courtney Miller, an associate professor at The Scripps Research Institute, was awarded a $472,500 Cutting Edge Basic Research Award by the National Institute on Drug Abuse to study models of the brain development of newborns who have been exposed to—and are addicted to—prescription pain medication while in the womb.

Read more:

Take-Back Events and Drop Boxes

Police Adding New Permanent Drug Drop-Off Station
KCCI (Iowa)
April 8, 2014

Portland Police Offer Way to Safely Dispose of Prescription Drugs
KII-TV (Texas)
April 7, 2014

Middlesex District Attorney Marian Ryan Provides Drug Collection Units for Four Communities
The Middlesex District Attorney's Office (Massachusetts)
April 4, 2014

Save the Dates

National Take-Back Initiative
Drug Enforcement Administration
April 26, 2014

Sixth Annual American Medicine Chest Challenge National Day of Awareness and Safe Disposal of Rx and OTC Medicine
American Medicine Chest Challenge
November 8, 2014

Upcoming Conferences and Workshops

Pharmacy Diversion Awareness Conference
U.S. Department of Justice, Drug Enforcement Administration
June 28 and 29, 2014: Renaissance Phoenix (Ariz.) Downtown
July 12 and 13, 2014: Sheraton Philadelphia (Pa.) Downtown Hotel
August 2 and 3, 2014: Denver (Colo.) Marriott Tech Center

National Rx Drug Abuse Summit
April 22–24, 2014
Atlanta, Georgia

RX for Prevention: Preventing and Responding to Prescription Drug Abuse on Campus
Temple University, Villanova University, U.S. Attorney's Office, and the Clery Center
June 11, 2014
Philadelphia, Pennsylvania

27th Annual NPN Prevention Research Conference
National Prevention Network
September 15–18, 2014

2014 Harold Rogers PDMP National Meeting
Brandeis University, Prescription Drug Monitoring Program Training and Technical Assistance Center
September 22–24, 2014
Washington, D.C.
The Weekly Update is a service provided by the SAMHSA Preventing Prescription Abuse in the Workplace Technical Assistance Center (PAW) to keep the field abreast of recent news and journal articles to assist in forming policy, research, and programs to reduce prescription drug misuse or abuse. Please note, the materials listed are not reflective of SAMHSA's or PAW's viewpoint or opinion and are not assessed for validity, reliability or quality. The Weekly Update should not be considered an endorsement of the findings. Readers are cautioned not to act on the results of single studies, but rather to seek bodies of evidence. Copyright considerations prevent PAW from providing full text of journal articles listed in the Weekly Update.